Then came a turning point. Juju became eligible for a clinical trial, supported in part by St. Baldrick’s, involving Blinatumomab, an immunotherapy drug that is showing remarkable results.
In the trial, children receiving Blinatumomab with traditional chemotherapy had a 96% three-year disease-free survival rate, compared to 87.9% with chemotherapy alone. Even better, the drug shows no evidence of causing long-term side effects, which is critical for young patients like Juju.
